Pfiz­er and BioN­Tech file BLA for Omi­cron-tar­get­ing Covid-19 vac­cine

Pfiz­er and BioN­Tech are seek­ing full ap­proval for their Omi­cron-tar­get­ed bi­va­lent Covid shot, and they’re fol­low­ing an FDA ad­vi­so­ry com­mit­tee’s ad­vice on “har­mo­niz­ing” vac­cine com­po­si­tions.

The part­ners have filed a sup­ple­men­tal BLA for their Omi­cron BA.4/BA.5-adapt­ed bi­va­lent Covid-19 vac­cine as both a pri­ma­ry dose or a boost­er for pa­tients over the age of 12. That means un­vac­ci­nat­ed chil­dren and adults could skip the orig­i­nal pri­ma­ry se­ries and re­ceive a bi­va­lent shot first.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER